Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth ...( SAN DIEGO Aug. 4 /-...)

SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference at the Intercontinental Hotel in Boston on August 13, 2009, 2:00 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President
    619-849-600
'/>"/>
SOURCE  Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 
Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
4. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
5. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
6. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
7. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
8. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
9. Brookstone Pharmaceuticals Appoints New Corporate Position
10. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
11. Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results